

# Key Takeaways: HIDDEN



## HFpEF

Heart failure with preserved ejection fraction in patients typically over 60 years old



## INTOLERANCE

to standard HF therapies, i.e., ACEi / ARB and beta blockers



## DISCORDANCE

between QRS voltage and LV wall thickness



## DIAGNOSIS

of carpal tunnel syndrome or lumbar spinal stenosis



## ECHO

showing increased LV wall thickness




## NERVOUS SYSTEM

Autonomic nervous system dysfunction, including GI complaints or unexplained weight loss

LV=left ventricular.

Mohammed SF, et al. JACC Heart Fail. 2014;2(2):113-122. Oerlemans MIFJ, et al. Neth Heart J. 2019;27(11):525-536. Maurer MS, et al. Circ Heart Fail. 2019 Sep;12(9):e006075.

## Increased clinical suspicion for ATTR-CM



hATTR-CM, hereditary transthyretin amyloid cardiomyopathy; IHC, immunohistochemistry; MGUS, monoclonal gammopathy of undetermined significance; TTR, transthyretin; wtATTR-CM, wild-type transthyretin amyloid cardiomyopathy. **References:** 1. Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. *Circ Heart Fail.* 2019;12(9):1-11. doi:10.1161/CIRCHEARTFAILURE.119.006075. 2. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. *Circulation.* 2016;133(24):2404-2412.